
Pancreatic cancer cells (blue) growing as a sphere encased in membranes (red). Photo credit: National Cancer Institute
Researchers discover unexpected role of an immune system receptor; blocking it halts human cancer cell growth and improves survival in animal models
For some cancers, initial treatment with chemotherapy brings positive, but only temporary, results: tumors shrink, but then rebound as the cancer becomes drug-resistant. This pattern of remission-resistance-relapse is particularly true for pancreatic cancer, an aggressive disease in which early success is often countered by eventual disease progression.
To wit: The one-year relative survival rate for pancreatic cancer is 20 percent, according to the American Cancer Society. The five-year rate is just 7 percent.
The reason: Current multidrug chemotherapy regimens targeting pancreatic cancer typically do not fully eradicate all cancer cells, leaving behind drug-resistant cells that harbor aberrant stem cell properties and can drive tumor regrowth and metastasis.
In a new paper publishing in the April 4, 2019 online issue of Cell, an international team of scientists led by researchers at University of California San Diego School of Medicine employed an array of next-generation sequencing and gene-editing tools, such as CRISPR, to map the molecular dependencies —and thus vulnerabilities — of pancreatic cancer stem cells.
Most notably, they found that a key hormone receptor called retinoic acid receptor-related orphan receptor gamma or ROR?, previously studied in inflammation and T-cell differentiation, was especially active during pancreatic cancer progression, and that blocking it markedly slowed patient derived tumor growth and improved survival in animal models.
“These studies revealed an unexpected role for immuno-regulatory genes in the maintenance of the most aggressive, drug-resistant cells in pancreatic cancer,” said senior study author Tannishtha Reya, PhD, UC San Diego professor in the departments of Pharmacology and Medicine. In particular, ROR? emerged as a key regulator. ROR? rose with cancer progression and its inhibition through genetic and pharmacological approaches resulted in a striking defect in pancreatic cancer growth.
“Our work shows that immune system signals are hijacked by pancreatic cancer, and suggests that therapies currently being tested for autoimmune indications should be considered for testing in pancreatic cancer,” said Reya.
Using genome scale approaches to map stem cell dependencies in pancreatic cancer “will be invaluable for understanding the basis of therapy resistance and recurrence and for discovering new vulnerabilities in pancreatic cancer,” said Reya. “Beyond providing new scientific insight, this work can help identify pathways for which clinical grade inhibitors may already exist and can thus be rapidly tested in pancreatic cancer.”
In particular, she said the discovery of ROR?‘s role in promoting tumor growth provides a new avenue for research and potential therapies. “One exciting aspect is the possibility that nuclear hormone receptors could represent therapeutic targets for pancreatic cancer. In fact, drugs targeting ROR? have already been developed by several pharmaceutical companies, and are in trials for autoimmune diseases. Our findings suggest that these agents could also be a valuable therapeutic strategy for pancreatic cancer.”
Learn more: Genome-Wide Analysis Reveals New Strategies to Target Pancreatic Cancer
The Latest on: Pancreatic cancer
[google_news title=”” keyword=”pancreatic cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Pancreatic cancer
- Cancer Patients: Find Out if Boswellia is Safe from Health Experts!on March 24, 2023 at 7:41 pm
But those that can already be proven are in breast cancer, pancreatic cancer, leukemia and brain cancers. → See more questions and expert answers related to Boswellia. Disclaimer: This is for ...
- Pancreatic Cancer Drugs Global Market Report 2023: Sector to Reach $4.6 Billion in 2027 at a CAGR of 4.1%on March 24, 2023 at 7:06 pm
DUBLIN, March 24, 2023 /PRNewswire/ -- The "Pancreatic Cancer Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides strategists, marketers ...
- Plymouth dad suffering from back pain dies from pancreatic cancer just weeks lateron March 24, 2023 at 4:02 pm
A Plymouth dad-of-two tragically died from pancreatic cancer just weeks after complaining of a sore back and being prescribed painkillers. Now his sister is sharing his story to fund desperately ...
- VCP/p97 as a therapeutic target in KRAS-mutant pancreatic canceron March 24, 2023 at 11:26 am
A new research paper, titled "VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in KRAS-mutant pancreatic cancer," was published ...
- Pancreatic cancer: New simple breath test could detect disease - signs and symptomson March 23, 2023 at 9:01 pm
Simply blowing into a bag at your GP surgery could help detect pancreatic cancer, thanks to a major scientific breakthrough. The highly aggressive disease has a lower survival rate than other ...
- Israeli scientists find how pancreatic cancer spreads and kills - studyon March 23, 2023 at 7:44 am
The new study, led by the Hebrew University of Jerusalem, opens the door to possible treatments for pancreatic cancer.
- Neutrophils Found to Be Culprits in Treatment-Resistant Pancreatic Canceron March 23, 2023 at 5:00 am
Researchers led by Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown for the first time exactly how immature neutrophils are hijacked by pancreatic ...
- Israeli scientists make breakthrough discovery to treat pancreatic canceron March 22, 2023 at 11:58 am
Pancreatic cancer is considered on of the deadliest and most violent types of cancer - Click the link for more details.
- Researchers identify neutrophils as major culprits in treatment resistance of pancreatic canceron March 22, 2023 at 7:14 am
Researchers have shown for the first time exactly how immature neutrophils—white blood cells that are an important part of the immune system—are hijacked by pancreatic cancers to drive ...
- Can a Smartphone App Help Prevent Malnutrition for Patients with Pancreatic Cancer?on March 22, 2023 at 12:01 am
Kea Turner, PhD, received a 2022 Career Development Award from PanCAN for a project titled “Remote Nutrition Monitoring for Metastatic Pancreatic Cancer Patients.” ...
via Bing News